Loading organizations...
§ Private Profile · Tukholmankatu 8, Helsinki, Uusimaa, 00290, Finland
Cloud-based AI software company providing medical image analysis for digital pathology, serving clinical and research labs.
Based in Helsinki, Finland, Aiforia develops cloud-based artificial intelligence software for analyzing medical images in clinical pathology and preclinical research. The publicly traded company operates a software-as-a-service platform that allows pathologists and scientists to automate tissue sample analysis and build custom diagnostic models without specialized hardware. Operating with approximately 150 employees, the enterprise raised roughly €30 million during its 2021 initial public offering and has processed over one million images to date. The platform currently serves over 5,000 users across more than 50 countries, supporting applications in breast cancer and neurodegenerative diseases. Aiforia provides its proprietary technology to major healthcare and academic institutions, including Mayo Clinic, MIT, Karolinska Institutet, and Boehringer Ingelheim. Originally established as a spin-off from the University of Helsinki, the company was founded in 2013 by Johan Lundin, Mikael Lundin, and Kari Pitkänen.
Aiforia has raised $32.7M across 2 funding rounds.
Aiforia has raised $32.7M in total across 2 funding rounds.
Aiforia has raised $32.7M across 2 funding rounds. Most recently, it raised $30.7M Series B in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 8, 2021 | $30.7M Series B | Epredia | Aktia Nordic Micro CAP | Announced |
| Nov 1, 2017 | $2M Series A | Ascend Capital Partners | Endeavor Venture Funds, Acme Investments, STO Rahoitus | Announced |
Aiforia is a publicly traded medical software company specializing in deep learning AI and cloud-based platforms for pathology image analysis. Founded in 2013 as a spin-off from the University of Helsinki and listed on Nasdaq Helsinki's First North Growth Market in 2021, it equips pathologists and scientists in clinical, pre-clinical, and academic labs with tools like the Aiforia® Platform, Aiforia® Create for AI model development, and Aiforia® Studies for study-centric workflows.[1][2][6] The company serves hospitals, health systems, pharma/biotech firms, contract research organizations, and academic institutions—such as Mayo Clinic, MIT, and Karolinska Institutet—solving the challenge of analyzing large, complex medical images by boosting speed, accuracy, and consistency to enable faster discoveries, decisions, and diagnoses.[1][4][6] Its recent launch of a next-generation platform with Vision Transformer architecture and a proprietary Foundation Engine accelerates AI training and analysis while maintaining transparency and generalizability across diverse datasets.[1]
Growth momentum includes thousands of AI models developed for research, several CE-IVD marked diagnostic solutions deployed (making it Europe's leading provider in digital pathology), and a global footprint with headquarters in Helsinki, Finland, plus U.S. offices in Cambridge, MA, and Rochester, MN, and representatives across Europe and North America.[1][6]
Aiforia emerged in 2013 as a spin-off from the University of Helsinki, leveraging early advancements in deep learning AI tailored for pathology image analysis.[1][6] The founding team, comprising experienced AI/software developers, pathologists, medical scientists, and commercial experts, addressed the limitations of manual image analysis in clinical and research settings, where pathologists faced overwhelming volumes of complex data.[1][2] Early traction built through pioneering commercial AI training tools for pathologists since 2018, followed by key milestones like the Aiforia® Clinical Suites, study-centric workflows, and the 2021 Nasdaq listing, which fueled expansion into subsidiaries in the U.S. and France.[1][6] Pivotal moments include deploying thousands of research AI models and CE-IVD certified diagnostics, solidifying its role in transforming pathology workflows.[1][3]
(Note: References to aiforia.co appear unrelated, focusing on general AI for non-medical sectors like voice assistants, and are excluded here.[5])
Aiforia rides the wave of AI-driven digital pathology, a trend accelerating with advances in whole-slide imaging, cloud computing, and foundation models amid rising demand for precision medicine.[1][2] Timing is ideal as global pathology labs grapple with pathologist shortages and data overload, while regulatory approvals like CE-IVD position it ahead in Europe's digitized healthcare shift and U.S. adoption via partners like Mayo Clinic.[1][6] Market forces favoring Aiforia include pharma's push for AI in drug discovery/response prediction (e.g., DECIDER project for treatment failure forecasting) and healthcare's move to AI-augmented diagnostics for faster, consistent outcomes.[3][6] It influences the ecosystem by democratizing AI model creation for domain experts, fostering thousands of custom models, and bridging research-to-clinic gaps, thus amplifying AI's impact on patient care and medical breakthroughs.[1][4]
Aiforia's trajectory points to expanded adoption of its Foundation Engine-powered platform, with potential for more CE-IVD diagnostics, U.S. FDA clearances, and pharma partnerships amid surging AI pathology demand.[1][6] Trends like multimodal AI integration, larger foundation datasets, and telepathology will shape its path, enhancing predictive analytics for personalized treatments. Its influence may evolve from research enabler to global diagnostic standard-setter, driving better patient outcomes as AI matures in regulated healthcare—cementing its role in translating images into life-saving decisions.[1][2]
Aiforia has raised $32.7M in total across 2 funding rounds.
Aiforia's investors include Epredia, Aktia Nordic Micro Cap, Ascend Capital Partners, Endeavor Venture Funds, ACME Investments, STO-Rahoitus.